Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Net Cash Flow (2016 - 2025)

Spyre Therapeutics' Net Cash Flow history spans 11 years, with the latest figure at $20.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 16.61% year-over-year to $20.8 million; the TTM value through Dec 2025 reached -$3.7 million, up 96.29%, while the annual FY2025 figure was -$3.7 million, 96.29% up from the prior year.
  • Net Cash Flow reached $20.8 million in Q4 2025 per SYRE's latest filing, up from -$16.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $200.1 million in Q2 2023 to a low of -$182.4 million in Q2 2024.
  • Average Net Cash Flow over 5 years is -$305850.0, with a median of -$183000.0 recorded in 2022.
  • Peak YoY movement for Net Cash Flow: tumbled 11226.75% in 2023, then surged 30582.54% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$9.5 million in 2021, then skyrocketed by 56.45% to -$4.1 million in 2022, then skyrocketed by 2445.66% to $97.3 million in 2023, then crashed by 81.65% to $17.9 million in 2024, then increased by 16.61% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Net Cash Flow are $20.8 million (Q4 2025), -$16.8 million (Q3 2025), and $33.2 million (Q2 2025).